• Source: Enavogliflozin

Enavogliflozin (DWP16001/GCC5694A) is an experimental selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity.




References

Kata Kunci Pencarian:

• Enavogliflozin
• Dapagliflozin
• Empagliflozin
• Henagliflozin
• SGLT2 inhibitor
• Glucose transporter
• Canagliflozin
• Dapagliflozin/sitagliptin
• Sodium-glucose transport proteins
• Velagliflozin